New glioblastoma drug (IMAGE)
Caption
A new type of small molecule drug, the first to target circadian clock proteins as a way to treat glioblastoma, is now in phase 1 clinical trials.
Credit
Issey Takahashi
Usage Restrictions
none
License
Original content